NBIX Neurocrine Biosciences, Inc.

41.77
-2  -5%
Previous Close 44.16
Open 44.66
Price To book 12.19
Market Cap 3.64B
Shares 87,114,000
Volume 1,237,193
Short Ratio 4.06
Av. Daily Volume 1,071,510

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 planned for 2017.
NBI-640756
Essential Tremor
NDA filing planned - license agreement with BIAL announced February 9, 2017.
Opicapone
Parkinson's disease
Phase 2 data due April 2017.
INGREZZA
Tourette syndrome - juvenile
Phase 2 data released January 18, 2017 did not meet primary endpoint.
INGREZZA
Tourette syndrome - adults
Phase 3 initiated by partner Abbvie in January 2016. Data due 4Q 2017.
Elagolix
Uterine Fibroids
First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA Filing due 3Q 2017.
Elagolix
Endometriosis
PDUFA date under priority review April 11, 2017. Announced January 5, 2017 that the Advisory Committee Meeting originally scheduled for February 16, 2016 has been cancelled.
INGREZZA
Tardive dyskinesia

Latest News

  1. 9:00 am Neurocrine Biosci announces the American Journal of Psychiatry published results from Kinect 3 Phase III Study of Ingrezza for the treatment of tardive dyskinesia; study met its primary endpoint
  2. Neurocrine Announces American Journal of Psychiatry Publication of Positive Results from Kinect 3 Phase III Study of INGREZZA TM (valbenazine) for the Treatment of Tardive Dyskinesia
  3. NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Other Events
  4. NEUROCRINE BIOSCIENCES INC Financials
  5. Neurocrine Biosciences, Inc. :NBIX-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017
  6. NBIX: Acquires North American Rights to ONGENTYS® For the Treatment of Parkinson’s Disease
  7. (2/15) Today's Top 10 Long/Short Estimize Signal Scores
  8. Edited Transcript of NBIX earnings conference call or presentation 14-Feb-17 10:00pm GMT
  9. NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
  10. Neurocrine reports 4Q loss
  11. Neurocrine reports 4Q loss
  12. Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017
  13. Q4 2016 Neurocrine Biosciences Inc Earnings Release - After Market Close
  14. NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Pri
  15. Neurocrine Inks $145 Million Parkinson's Drug Deal
  16. Neurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone
  17. Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results
  18. (2/7) Today's Top 10 Long/Short Estimize Signal Scores
  19. Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : February 1, 2017
  20. Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen
  21. Neurocrine Biosci upgraded by Oppenheimer
  22. NBIX: Phase 2 Study of INGREZZA™ in Adults with Tourette Syndrome Fails to Hit Primary Endpoint
  23. After hours buzz: CSX, UAL, GIMO & more
  24. Neurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment of Tardive Dyskinesia
  25. Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down
  26. Neurocrine Biosciences Reports Third Quarter 2016 Results
  27. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2016 Results
  28. Neurocrine Announces INGREZZA™ (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia has been Accepted for Priority Review by U.S. FDA
  29. Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia
  30. Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA™ for VMAT2 Inhibitor Valbenazine
  31. Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA™ for VMAT2 Inhibitor Valbenazine
  32. Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia
  33. Neurocrine Biosciences Reports Second Quarter 2016 Results
  34. Neurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome
  35. Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2016 Results
  36. Neurocrine Biosciences to Present at the Jefferies 2016 Healthcare Conference
  37. Neurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors
  38. Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
  39. Neurocrine Biosciences Announces Additional Valbenazine (NBI-98854) Data to be Presented at the American Psychiatric Association's 2016 Annual Meeting in Atlanta
  40. Neurocrine Biosciences Reports First Quarter 2016 Results
  41. Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2016 Results
  42. Neurocrine Biosciences to Present at the Deutsche Bank 41st Annual Health Care Conference